Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulbactam Sodium

FDA-approved product (injectable, injection).

Registered studies
50+
Lab records
20
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulbactam Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase inhibitors
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CG01

Repurposing investigation

Sulbactam Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae18.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis26.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 2 of 5 lab records
  • E. coli: measured active in 10 of 13 lab records
  • K. pneumoniae: measured active in 0 of 2 lab records
Open Sulbactam Sodium in ChEMBL Registered studies below
Show the 20 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-4.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulbactam Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antibacterial Tactics Based on Presepsin Level in Thoracic Aorta Surgery Patients

    NCT06336213 · start 2024-01-23

    Registered record
    Registry ID
    NCT06336213
    Conditions
    Aortic Aneurysm and Dissection; Cardiac Valve Disease; Thoracic Aortic Aneurysm; Thoracic Aortic Dissection
    Interventions
    Ampicillin-sulbactam
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-01-23
    Completion
    2027-02-15
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAortic Aneurysm and Dissection; Cardiac Valve Disease; Thoracic Aortic Aneurysm; Thoracic Aortic Dissection
    InterventionAmpicillin-sulbactam
    PhaseNot applicable
    Registry statusRecruiting

  • Comparing Oral Versus Parenteral Antimicrobial Therapy

    NCT05977868 · start 2023-08-04

    Registered record
    Registry ID
    NCT05977868
    Conditions
    Endovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection; Gastrointestinal Infection; Genitourinary Infection
    Interventions
    Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid; Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-08-04
    Completion
    2025-02-14
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection +2 more
    InterventionAmoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid; Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
    PhasePhase 4
    Registry statusTerminated

  • Prevention of Cefoperazone-induced Coagulopathy

    NCT05742295 · start 2023-02-25

    Registered record
    Registry ID
    NCT05742295
    Conditions
    Antibiotic Side Effect
    Interventions
    Vitamin K
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-02-25
    Completion
    2023-10-05
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic Side Effect
    InterventionVitamin K
    PhasePhase 4
    Registry statusCompleted

  • Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia

    NCT04724044 · start 2021-01-25

    Registered record
    Registry ID
    NCT04724044
    Conditions
    Community-acquired Pneumonia; Sepsis; Inflammatory Response; Mortality; Biomarkers; SIRS
    Interventions
    Tablets; Clarithromycin 500mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-01-25
    Completion
    2023-04-11
    Enrolment
    278

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-acquired Pneumonia; Sepsis; Inflammatory Response; Mortality +2 more
    InterventionTablets; Clarithromycin 500mg
    PhasePhase 3
    Registry statusCompleted

  • Effects of Nasal-spraying LiveSpo Navax in Treatment of Acute Respiratory Infections in Children

    NCT05164692 · start 2020-08-29

    Registered record
    Registry ID
    NCT05164692
    Conditions
    Acute Respiratory Tract Infections
    Interventions
    LiveSpo Navax; 0.9% NaCl physiological saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-08-29
    Completion
    2021-08-29
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Respiratory Tract Infections
    InterventionLiveSpo Navax; 0.9% NaCl physiological saline
    PhaseNot applicable
    Registry statusCompleted

  • Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

    NCT03894046 · start 2019-09-05

    Registered record
    Registry ID
    NCT03894046
    Conditions
    Acinetobacter Baumannii-calcoaceticus Complex; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; Bacteremia; Colistin Resistant ABC
    Interventions
    Sulbactam; Durlobactam; Colistin; Imipenem/Cilastatin 500 mg/500 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-09-05
    Completion
    2021-07-26
    Enrolment
    207

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinetobacter Baumannii-calcoaceticus Complex; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; Bacteremia +1 more
    InterventionSulbactam; Durlobactam; Colistin; Imipenem/Cilastatin 500 mg/500 mg
    PhasePhase 3
    Registry statusCompleted

  • Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

    NCT03310463 · start 2017-10-03

    Registered record
    Registry ID
    NCT03310463
    Conditions
    Acinetobacter Baumannii Infection
    Interventions
    ETX2514SUL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-10-03
    Completion
    2018-05-29
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinetobacter Baumannii Infection
    InterventionETX2514SUL
    PhasePhase 1
    Registry statusCompleted

  • Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects

    NCT03303924 · start 2017-08-21

    Registered record
    Registry ID
    NCT03303924
    Conditions
    Healthy
    Interventions
    ETX2514 and sulbactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-08-21
    Completion
    2017-10-26
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionETX2514 and sulbactam
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

    NCT02971423 · start 2016-10

    Registered record
    Registry ID
    NCT02971423
    Conditions
    Acinetobacter Baumannii Infection
    Interventions
    ETX2514; Placebo; Sulbactam; Imipenem/Cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-10
    Completion
    2017-06-01
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinetobacter Baumannii Infection
    InterventionETX2514; Placebo; Sulbactam; Imipenem/Cilastatin
    PhasePhase 1
    Registry statusCompleted

  • A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea

    NCT04202068 · start 2015-07-03

    Registered record
    Registry ID
    NCT04202068
    Conditions
    Gonorrhea
    Interventions
    Ceftriaxone sodium and Sulbactam Sodium for injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-07-03
    Completion
    2016-05-30
    Enrolment
    113

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGonorrhea
    InterventionCeftriaxone sodium and Sulbactam Sodium for injection
    PhasePhase 4
    Registry statusCompleted

  • PHase IV Clinical Trial of Ceftriaxone Sodium and Sulbactam Sodium for Injection (CRO-SBT)

    NCT04066621 · start 2015-04-28

    Registered record
    Registry ID
    NCT04066621
    Conditions
    Respiratory Tract Infections; Urinary Tract Infections in Children
    Interventions
    Ceftriaxone Sodium and Sulbactam Sodium for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-04-28
    Completion
    2017-05-27
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRespiratory Tract Infections; Urinary Tract Infections in Children
    InterventionCeftriaxone Sodium and Sulbactam Sodium for Injection
    PhasePhase 4
    Registry statusCompleted

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria

    NCT03477422 · start 2014-01-11

    Registered record
    Registry ID
    NCT03477422
    Conditions
    Urinary Tract Infection Complicated; Acute Pyelonephritis
    Interventions
    CSE-1034 (Ceftriaxone + Sulbactam + EDTA); Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-01-11
    Completion
    2017-05-08
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection Complicated; Acute Pyelonephritis
    InterventionCSE-1034 (Ceftriaxone + Sulbactam + EDTA); Meropenem
    PhasePhase 3
    Registry statusCompleted

  • Concentration of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients

    NCT02007603 · start 2013-08

    Registered record
    Registry ID
    NCT02007603
    Conditions
    Infection During Hemodialysis
    Interventions
    Administration of Amoxicillin / clavulanic acid; Ampicillin / sulbactam; Blooddraws for pharmacokinetic profiling
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-08
    Completion
    2017-05
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection During Hemodialysis
    InterventionAdministration of Amoxicillin / clavulanic acid; Ampicillin / sulbactam; Blooddraws for pharmacokinetic profiling
    PhasePhase 3
    Registry statusCompleted

  • Antibiotic Prophylaxis in Laparoscopic Cholecystectomy

    NCT01888822 · start 2013-06

    Registered record
    Registry ID
    NCT01888822
    Conditions
    Cholelithiasis
    Interventions
    Ciprofloxacin; Ampicillin-sulbactam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2013-06
    Completion
    2017-06
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholelithiasis
    InterventionCiprofloxacin; Ampicillin-sulbactam; Placebo
    PhasePhase 4
    Registry statusTerminated